Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of ALXN1850 in Adults with Hypophosphatasia
NCT04980248Phase 1Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Sep 2021
- Primary completion
- Aug 2022
- Modality
- Replacement Enzymes, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of efzimfotase alfa in hypophosphatasia (HPP), sponsored by Alexion Pharmaceuticals. Primary endpoint: Number of Participants With Treatment Emergent Adverse Events and Treatment Emergent Serious Adverse Events. Started Sep 2021; status: completed.
02
Drugs
efzimfotase alfa
03
Conditions
hypophosphatasia (HPP)
Beyond the preview
Go deeper on NCT04980248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04980248.